SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
5 Unspoken Rules You Need to Know When Starting a Media Agency
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
5 Unspoken Rules You Need to Know When Starting a Media Agency
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
5 Unspoken Rules You Need to Know When Starting a Media Agency
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
5 Unspoken Rules You Need to Know When Starting a Media Agency
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
NASDAQ:NURO

NeuroMetrix - NURO Stock Forecast, Price & News

$2.71
-0.03 (-1.09%)
(As of 10/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.67
$2.79
50-Day Range
$2.71
$4.10
52-Week Range
$2.67
$10.10
Volume
25,855 shs
Average Volume
34,660 shs
Market Capitalization
$19.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NURO stock logo

About NeuroMetrix (NASDAQ:NURO) Stock

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Receive NURO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter.

NURO Stock News Headlines

NeuroMetrix Reports Q2 2022 Financial Results
See More Headlines
Receive NURO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter.

NURO Company Calendar

Last Earnings
7/21/2022
Today
10/07/2022
Next Earnings (Estimated)
10/20/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NURO
Employees
23
Year Founded
1996

Profitability

Net Income
$-2,280,000.00
Pretax Margin
-45.75%

Debt

Sales & Book Value

Annual Sales
$8.25 million
Book Value
$3.48 per share

Miscellaneous

Free Float
6,631,000
Market Cap
$19.32 million
Optionable
Not Optionable
Beta
2.53

Social Links


Key Executives

  • Dr. Shai N. Gozani M.D. (Age 57)
    Ph.D., Founder, Chairman, CEO, Pres & Sec.
    Comp: $557.66k
  • Mr. Thomas T. HigginsMr. Thomas T. Higgins (Age 70)
    Sr. VP, CFO & Treasurer
    Comp: $414.38k
  • Dr. Xuan Kong Ph.D.
    Chief Data Scientist
  • Ms. Susan M. Bell R.N.
    Sr. VP of Population Health & Value Based Care













NURO Stock - Frequently Asked Questions

How have NURO shares performed in 2022?

NeuroMetrix's stock was trading at $5.02 at the beginning of 2022. Since then, NURO stock has decreased by 46.0% and is now trading at $2.71.
View the best growth stocks for 2022 here
.

When is NeuroMetrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 20th 2022.
View our NURO earnings forecast
.

How were NeuroMetrix's earnings last quarter?

NeuroMetrix, Inc. (NASDAQ:NURO) issued its quarterly earnings data on Thursday, July, 21st. The medical device company reported ($0.17) EPS for the quarter. The medical device company had revenue of $2.14 million for the quarter. NeuroMetrix had a negative net margin of 45.76% and a negative trailing twelve-month return on equity of 16.02%.

When did NeuroMetrix's stock split?

NeuroMetrix's stock reverse split on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What is Shai N. Gozani's approval rating as NeuroMetrix's CEO?

10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeuroMetrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), Ampio Pharmaceuticals (AMPE), ReWalk Robotics (RWLK), Aurora Cannabis (ACB), Advanced Micro Devices (AMD) and Vaxart (VXRT).

What is NeuroMetrix's stock symbol?

NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO."

How do I buy shares of NeuroMetrix?

Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuroMetrix's stock price today?

One share of NURO stock can currently be purchased for approximately $2.71.

How much money does NeuroMetrix make?

NeuroMetrix (NASDAQ:NURO) has a market capitalization of $19.32 million and generates $8.25 million in revenue each year. The medical device company earns $-2,280,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

How can I contact NeuroMetrix?

NeuroMetrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The official website for the company is www.neurometrix.com. The medical device company can be reached via phone at (781) 890-9989, via email at neurometrix.ir@neurometrix.com, or via fax at 302-636-5454.

This page (NASDAQ:NURO) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.